Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
2009 1
2010 1
2011 1
2012 2
2013 10
2014 4
2015 21
2016 15
2017 15
2018 3
2019 4
2020 2
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 27618663

74 results
Results by year
Filters applied: . Clear all
Page 1
Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant.
Pascolutti R, Sun X, Kao J, Maute RL, Ring AM, Bowman GR, Kruse AC. Pascolutti R, et al. Structure. 2016 Oct 4;24(10):1719-1728. doi: 10.1016/j.str.2016.06.026. Epub 2016 Sep 8. Structure. 2016. PMID: 27618663 Free PMC article.
Molecular dynamics simulations elucidate conformational selection and induced fit mechanisms in the binding of PD-1 and PD-L1.
Liu W, Huang B, Kuang Y, Liu G. Liu W, et al. Mol Biosyst. 2017 May 2;13(5):892-900. doi: 10.1039/c7mb00036g. Mol Biosyst. 2017. PMID: 28327740
The design of high affinity human PD-1 mutants by using molecular dynamics simulations (MD).
Du J, Qin Y, Wu Y, Zhao W, Zhai W, Qi Y, Wang C, Gao Y. Du J, et al. Cell Commun Signal. 2018 Jun 7;16(1):25. doi: 10.1186/s12964-018-0239-9. Cell Commun Signal. 2018. PMID: 29879980 Free PMC article.
Human PD-1 binds differently to its human ligands: a comprehensive modeling study.
Viricel C, Ahmed M, Barakat K. Viricel C, et al. J Mol Graph Model. 2015 Apr;57:131-42. doi: 10.1016/j.jmgm.2015.01.015. Epub 2015 Feb 14. J Mol Graph Model. 2015. PMID: 25723350
PD-L1 Nanobody Competitively Inhibits the Formation of the PD-1/PD-L1 Complex: Comparative Molecular Dynamics Simulations.
Sun X, Yan X, Zhuo W, Gu J, Zuo K, Liu W, Liang L, Gan Y, He G, Wan H, Gou X, Shi H, Hu J. Sun X, et al. Int J Mol Sci. 2018 Jul 7;19(7):1984. doi: 10.3390/ijms19071984. Int J Mol Sci. 2018. PMID: 29986511 Free PMC article.
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.
Chen N, Fang W, Zhan J, Hong S, Tang Y, Kang S, Zhang Y, He X, Zhou T, Qin T, Huang Y, Yi X, Zhang L. Chen N, et al. J Thorac Oncol. 2015 Jun;10(6):910-23. doi: 10.1097/JTO.0000000000000500. J Thorac Oncol. 2015. PMID: 25658629 Free article.
Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1).
Zak KM, Grudnik P, Guzik K, Zieba BJ, Musielak B, Dömling A, Dubin G, Holak TA. Zak KM, et al. Oncotarget. 2016 May 24;7(21):30323-35. doi: 10.18632/oncotarget.8730. Oncotarget. 2016. PMID: 27083005 Free PMC article.
Structure and interactions of the human programmed cell death 1 receptor.
Cheng X, Veverka V, Radhakrishnan A, Waters LC, Muskett FW, Morgan SH, Huo J, Yu C, Evans EJ, Leslie AJ, Griffiths M, Stubberfield C, Griffin R, Henry AJ, Jansson A, Ladbury JE, Ikemizu S, Carr MD, Davis SJ. Cheng X, et al. J Biol Chem. 2013 Apr 26;288(17):11771-85. doi: 10.1074/jbc.M112.448126. Epub 2013 Feb 15. J Biol Chem. 2013. PMID: 23417675 Free PMC article.
A high-affinity human PD-1/PD-L2 complex informs avenues for small-molecule immune checkpoint drug discovery.
Tang S, Kim PS. Tang S, et al. Proc Natl Acad Sci U S A. 2019 Dec 3;116(49):24500-24506. doi: 10.1073/pnas.1916916116. Epub 2019 Nov 14. Proc Natl Acad Sci U S A. 2019. PMID: 31727844 Free PMC article.
Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
Meng X, Huang Z, Teng F, Xing L, Yu J. Meng X, et al. Cancer Treat Rev. 2015 Dec;41(10):868-76. doi: 10.1016/j.ctrv.2015.11.001. Epub 2015 Nov 10. Cancer Treat Rev. 2015. PMID: 26589760 Review.
74 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page